Evolution of blast counts of patients treated with SU11248. Blast counts of patients treated with 50 mg SU11248 for 4 weeks followed by 2 weeks of rest (top panel); with 50 mg for 4 weeks followed by 1 week of rest (middle panel); and with 75 mg daily followed by 2 weeks of rest. FLT3 mutational status is indicated in the legend.